See the DrugPatentWatch profile for Xalkori
Is there a generic Xalkori (crizotinib) yet?
Xalkori is the brand name for crizotinib. Whether a true generic is available depends on jurisdiction and on each country’s drug-approval status. If you tell me your country (or whether you’re in the US, UK, Canada, EU, etc.), I can narrow this to the correct “generic approved/available” answer.
What counts as a “generic” for Xalkori?
People may mean different products:
- A true generic crizotinib (same active ingredient as Xalkori, approved as bioequivalent in that market).
- An “authorized generic” (branded under different packaging but still the same drug).
- A biosimilar does not apply here because crizotinib is a small-molecule targeted therapy, not a biologic.
How to check if a generic crizotinib is approved where you live
Look for:
- The active ingredient name “crizotinib” on the product label.
- Approval by your national regulator (for example, FDA in the US).
- A listing in your country’s drug database or national formulary.
If you share your location, I can tell you exactly what to search for and where (e.g., FDA Orange Book in the US).
What patients typically ask: can I switch from Xalkori to generic?
Whether a switch is safe depends on:
- Your cancer type and line of therapy.
- Your current dose and how you tolerate it.
- How quickly your treatment plan needs to start.
In practice, any approved generic should match the brand in active ingredient and dosing strength, but you may still need prescriber guidance and monitoring after the switch.
Price and availability: why “generic” may not be cheaper right away
Even after approval, costs can lag due to:
- Patent/exclusivity and launch timing.
- Limited early supply.
- Distribution and formulary decisions by insurers and hospitals.
If you tell me your country and whether you need help with insurance/coverage vs cash pay, I can tailor the guidance.
If no generic exists yet, what alternatives are used?
Alternatives can include:
- The brand drug (Xalkori).
- Other approved targeted therapies depending on your indication (because crizotinib is used for specific cancers with specific biomarkers).
- Participation in clinical trials when appropriate.
What I need from you to give a precise answer
Reply with:
1) Your country (or state/province), and
2) Whether you mean “generic approved” or “cheapest available right now,” and
3) Your indication if you know it (e.g., ALK-positive NSCLC, ROS1-positive NSCLC).